Abstract

Patients of colour predominately present with acral lentiginous melanoma (ALM), the most lethal subtype of cutaneous melanoma. We here advocate for increased mechanistic studies using models derived from the patient communities suffering most from ALM to develop therapies that benefit patients across all ethnic and racial groups. In this Comment article, Alicea and Rebecca advocate for increased basic research and translational studies of acral lentiginous melanoma using the patient communities that suffer the most in order to develop therapies that benefit patients across all ethnic and racial groups.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call